We’re excited to announce our collaboration with Mayo Clinic to further develop our fully synthetic and biodegradable bone graft material, Adaptos®. This collaboration focuses on advancing Adaptos® for new indications, aiming for FDA approval in the U.S. market.

“A significant milestone for the company. Through this collaboration, we gain valuable input from the fields leading surgeons to further develop our products, enhancing patient care and its efficiency. We extend our thanks to Business Finland, whose networks facilitated the in itial discussions for this collaboration,” says Pasi Kankaanpaa, CEO of Biomendex.

Mayo Clinic has financial interests in the technology referenced in this post. The clin ic uses the revenue it receives to support its nonprofit mission in patient care, education, and research.